ReviewMicroorganisms2019
Probiotics and Prebiotics for the Amelioration of Type 1 Diabetes: Present and Future Perspectives.
Review in Microorganisms, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05571865 (Preventing Diabetic Cardiomyopathy and Heart Failure by Ketone Bodies), which is not on this map. Cited by 61 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Preventing Diabetic Cardiomyopathy and Heart Failure by Ketone Bodies
Who cites it
61 citing papers in PubMed, 4 syntheses or guidelines pooled it, 127 citations in OpenAlex.
- Probiotics Supplementation for Improving Glucolipid Parameters in Individuals with Prediabetes: A Systematic Review and Meta-Analysis of Randomized Trials.Probiotics and antimicrobial proteins · 2025Pooled it
- Effects of probiotic supplementation on islet β-cell function in subjects with glucose metabolism disorders: a meta-analysis.Frontiers in nutrition · 2025Pooled it
- The Effect of Microbiome-Modulating Agents (MMAs) on Type 1 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Nutrients · 2024Pooled it
- Use of probiotics and similar in pediatric patients with Type 1 Diabetes Mellitus: a systematic review.Revista paulista de pediatria : orgao oficial da Sociedade de Pediatria de Sao Paulo · 2024Pooled it
- The effect of oral probiotics on glycated haemoglobin levels in children with type 1 diabetes mellitus - a randomized clinical trial.Pediatric endocrinology, diabetes, and metabolism · 2023Trial
- Adjuvant Probiotics ofFrontiers in endocrinology · 2022Trial
- Lack of effect ofBMJ open diabetes research & care · 2021Trial
- Probiotic and paraprobiotic intervention modulates testicular DNA methylation in streptozotocin-induced diabetic rats: insights into the role of Lactobacillus rhamnosus GG.Scientific reports · 2026Article
- The potential of microbiome modulators to improve quality of life in cancer survivors through gut microbiome-immune interactions.Frontiers in molecular neuroscience · 2026Review
- Age-Related Cognitive Decline and Dementia: Interface of Microbiome-Immune-Neuronal Interactions.The journals of gerontology. Series A, Biological sciences and medical sciences · 2025Review
- Exploring the Potential of Novel Animal-Origin Probiotics as Key Players in One Health: Opportunities and Challenges.International journal of molecular sciences · 2025Review
- The gut-heart axis: unveiling the roles of gut microbiota in cardiovascular diseases.Frontiers in cardiovascular medicine · 2025Review
- Role of Gut Microbiota in the Development of Some Autoimmune Diseases.Journal of inflammation research · 2025Review
- Functional Modulation of Gut Microbiota and Blood Parameters in Diabetic Rats Following Dietary Intervention with Free or ImmobilizedNutrients · 2024Article
- New horizon of the combined BCG vaccine with probiotic and liraglutide in augmenting beta cell survivalHeliyon · 2024Article
- Effects of Free or ImmobilizedMicroorganisms · 2024Article
- Recent progresses in gut microbiome mediates obstructive sleep apnea-induced cardiovascular diseases.FASEB bioAdvances · 2024Review
- Engineering Probiotics for Diabetes Management: Advances, Challenges, and Future Directions in Translational Microbiology.International journal of nanomedicine · 2024Review
- The role of GABA in type 1 diabetes.Frontiers in endocrinology · 2024Review
- A critical review on diabetes mellitus type 1 and type 2 management approaches: from lifestyle modification to current and novel targets and therapeutic agents.Frontiers in endocrinology · 2024Review
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
Abstract
Type 1-diabetes (T1D) is an autoimmune disease characterized by immune-mediated destruction of pancreatic beta (β)-cells. Genetic and environmental interactions play an important role in immune system malfunction by priming an aggressive adaptive immune response against β-cells. The microbes inhabiting the human intestine closely interact with the enteric mucosal immune system. Gut microbiota colonization and immune system maturation occur in parallel during early years of life; hence, perturbations in the gut microbiota can impair the functions of immune cells and vice-versa. Abnormal gut microbiota perturbations (dysbiosis) are often detected in T1D subjects, particularly those diagnosed as multiple-autoantibody-positive as a result of an aggressive and adverse immunoresponse. The pathogenesis of T1D involves activation of self-reactive T-cells, resulting in the destruction of β-cells by CD8⁺ T-lymphocytes. It is also becoming clear that gut microbes interact closely with T-cells. The amelioration of gut dysbiosis using specific probiotics and prebiotics has been found to be associated with decline in the autoimmune response (with diminished inflammation) and gut integrity (through increased expression of tight-junction proteins in the intestinal epithelium). This review discusses the potential interactions between gut microbiota and immune mechanisms that are involved in the progression of T1D and contemplates the potential effects and prospects of gut microbiota modulators, including probiotic and prebiotic interventions, in the amelioration of T1D pathology, in both human and animal models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.